Skip to content
    ECOR
    Earnings call· Jun 2026(Q2 FY26)

    electroCore Q2 FY26 earnings call ECOR

    Aug 6, 2026 Source

    Executive summary

    electroCore Q2 FY26 — Raised Revenue Guidance and Path to Positive EBITDA

    electroCore delivered strong Q2 FY26 results, marked by significant revenue growth and improved profitability, driven by strategic commercial reorganization and product diversification. The company raised its full-year revenue guidance and outlined a clear path to achieving positive adjusted EBITDA by Q3 2027, leveraging existing capital resources. Despite some operational headwinds, management expressed confidence in its multi-catalyst platform strategy in bioelectronic medicine.

    Highlights

    5

    • Q2 FY26 revenue increased approximately 28% year-over-year to $9.5 million.

    • Adjusted EBITDA improved 26% year-over-year to a loss of $1.8 million.

    • GAAP net loss improved 17% year-over-year to $3.1 million.

    • Quell product line sales grew approximately 700% year-over-year to $1.3 million.

    • Full-year 2026 revenue guidance raised to greater than 30% growth over FY25.

    Concerns

    5

    • Truvaga media efficiency ratio decreased to 1.91 due to increased competition and 30% higher cost per click.

    • FDA issued a preliminary 483 letter with four observations, delaying the potential relaunch of Quell 2.0.

    • A staffing issue at one VA facility caused a backlog of approximately $145,000 in revenue, pushing it to Q3 FY26.

    • Gross margin slightly decreased from 87.3% to 86.5% primarily due to an increase in inventory reserve.

    • Top 15 VA accounts produce 54% of Q2 VA revenue, indicating concentration risk.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year 2026 Revenue Growth
    greater than 30% growth
    high materiality
    High
    Adjusted EBITDA
    positive
    high materiality
    High
    Incentive Compensation Variable Expense
    approximately 27%
    medium materiality
    Medium
    Overall Sales and Marketing Expense
    approximately 54%
    medium materiality
    Medium
    G&A Expenses from Transaction Fees
    cut roughly 3%
    medium materiality
    Medium
    Quell 2.0 Relaunch
    delayed
    medium materiality
    High
    FDA Submission for CIPN (Quell device)
    completion by year-end
    high materiality
    High
    Refill Rate Increase
    30%
    medium materiality
    Medium

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Prescription gammaCore (VA)
    Growth was impacted by commercial reorganization and a temporary staffing issue at one VA facility, pushing $145,000 in revenue to Q3. Focus is shifting to new patient starts and increasing refill rates.
    Cumulative VA patients: 16,400Penetration of estimated addressable VA headache market: 2.7%
    		—11%-4%—
    Quell Product Line
    Strong growth driven by Quell Fibromyalgia sales into the VA. The company sees significant opportunity in active duty military and is expanding training for sales teams.
    Cumulative Quell revenue since May 2025 acquisition: $4MQuell Fibromyalgia sold into VA: $3.8M
    		$1.3M700%30%—
    Truvaga (OTC Wellness)
    Growth achieved despite increased competition in the health and wellness space, leading to higher media costs and reduced media efficiency. Media spend was reduced by 2%.
    		$1.3M27%——

    Operational metrics

    22
    Adjusted EBITDA Net Loss
    $1.8M26% year-over-year improvement; 25% sequential improvement
    Q2 FY26

    Compared to a $2.4 million adjusted EBITDA net loss in Q2 FY25.

    GAAP Net Loss
    $3.1M17% improvement year-over-year
    Q2 FY26

    Compared to a $3.7 million GAAP net loss in Q2 FY25.

    Net Loss Per Share
    $0.33vs $0.44 in Q2 FY25
    Q2 FY26

    Per share net loss for the quarter.

    Cash, Cash Equivalents and Marketable Securities
    $10Mvs $11.6M at December 31, 2025
    June 30, 2026

    Balance sheet cash position.

    Gross Profit Increase
    $1.7M
    Q2 FY26

    Increase in gross profit compared to Q2 FY25, reaching $8.2 million.

    R&D Expense
    $0.8Mvs $0.5M in Q2 FY25
    Q2 FY26

    Increase primarily due to increased studies and grants, higher stock-based compensation, and initial costs for Truvaga mobile app enhancements.

    SG&A Expense
    $10.1Mvs $9.4M in Q2 FY25
    Q2 FY26

    Total Selling, General & Administrative Expense.

    Sales & Marketing Expense Increase
    $1.4Myear-over-year
    Q2 FY26

    Increase primarily driven by variable expenses supporting the increase in net sales, reflecting operating leverage.

    G&A Expense Decrease
    $0.7Myear-over-year
    Q2 FY26

    Decrease primarily due to a $0.5 million reduction in bad debt expense and lower professional fees.

    Total Operating Expenses
    $10.9Mvs $9.9M in Q2 FY25
    Q2 FY26

    Total operating expenses for the quarter.

    Cash Used for Growth Investments
    $1M
    Q2 FY26

    Capital deployed towards growth initiatives.

    Organic Revenue Growth Rate
    28%year-over-year
    Q2 FY26

    Overall net sales growth for the quarter.

    Truvaga Media Efficiency Ratio
    1.91
    Q2 FY26

    Reduced due to increased competition and higher cost to acquire customers.

    Truvaga Cost Per Click
    30%increased
    Q2 FY26

    Direct cost per click for acquiring a customer increased.

    Truvaga Media Spend
    2%reduced
    Q2 FY26

    Reduced in response to increased cost of advertising, while still driving year-over-year growth.

    Competitors Bidding on Truvaga Search Terms
    860% increase from 5 in H1 2025
    H1 2026

    Increased competition in the health and wellness space.

    VA Medical Centers Covered by New 1099 Reps
    29approximately 20% of national network
    Q2 FY26

    17 new 1099 sales representatives were recruited and trained.

    Top Accounts Revenue Concentration
    54%
    Q2 FY26

    Top 15 accounts produce 54% of Q2 VA revenue, highlighting concentration risk.

    Backlogged Revenue
    $145,000
    Q2 FY26

    Due to a staffing issue in the prosthetics department of one VA facility; orders were fulfilled in July.

    Fibromyalgia Prevalence (US Service Members)
    2.2%
    before deployment

    Prevalence among male and female US service members before deployment, according to Rheumatology Advisor.

    Fibromyalgia Prevalence (US Service Members)
    8-11.1%
    after deployment

    Prevalence among male and female US service members after deployment, according to Rheumatology Advisor.

    Consistent Monthly Utilization Target
    75%
    ongoing

    Target for consistent monthly utilization within VA accounts, part of new KPI focus.

    Industry KPIs

    8
    MetricValueDetails
    System utilization75%%
    New product launch rampQuell 2.0
    FCF conversion leverage guidancegreater than 30%%
    Installed base system placements16,400patients
    Segment franchise organic growth28%%
    Sales force commercial capacity build17reps
    Indicated addressable patient population2.7%%
    Pivotal trial clinical evidence milestonesFDA submission for CIPN (Quell device)

    Product announcements

    2
    ProductTypeDetails
    Quell 2.0discontinuation
    Next-Generation Clinical Deviceroadmap

    Deals & partnerships

    1
    Lovell Government ServicesSole federal supply schedule contract holder across all electroCore products in VA and Department of Defense markets.

    Simplifies product movement through federal procurement, aligns with VA's request for veteran-owned groups, and provides access to DAPA, ECAT, and a web store. Lovell is an expert in federal ordering systems.

    Risks & headwinds

    5
    FDA 483 Letter and Quell 2.0 Relaunch Delaynear term

    4 observations and 2 discussion points cited

    Mitigation: Responded with corrective actions; changes expected to result in a stronger product and brand over time.

    Increased Media Costs and Competition for TruvagaQ2 FY26

    Media efficiency ratio of 1.91; direct cost per click increased ~30%; 60% increase in competitors (from 5 to 8) bidding on branded search terms.

    Mitigation: Reduced media spend by 2% while still driving year-over-year growth; focusing on new marketing strategies.

    VA Staffing Issue Causing Revenue BacklogQ2 FY26 impact, Q3 FY26 recognition

    Approximately $145,000 in revenue pushed from Q2 FY26 to Q3 FY26.

    Mitigation: Expanding breadth of facilities selling and fulfilling prescription products to diversify revenue and mitigate concentration risk; orders were fulfilled in July.

    Gross Margin DecreaseQ2 FY26

    Decreased from 87.3% to 86.5%

    Mitigation: Primarily due to an increase in inventory reserve; company guides for sustainable 85% gross profit margin.

    Revenue Concentration in VA Accountsongoing

    Top 15 accounts produce 54% of Q2 VA revenue.

    Mitigation: Diversifying revenue across more facilities, increasing breadth and depth in different accounts, and expanding into new federal channels.

    What to watch in Q3 FY26

    5

    Positive Adjusted EBITDA

    Q3 FY27
    Current($1.8M) loss in Q2 FY26
    Targetpositive

    Why it matters

    Achieving positive adjusted EBITDA is a key financial milestone and indicates sustainable profitability without further dilutive capital raises.

    we believe the operating improvements described today position us to execute our plan of achieving positive adjusted EBITDA in the third quarter of 2027.

    Q&A highlights

    5

    Can you provide more detail on the sales and marketing expense for the second half of the year, specifically regarding the addition of 1099 and W-2 sales representatives and how it relates to H2 spend versus H1?

    The addition of 1099 sales reps is commission-based, so it's a percentage of revenue and not an additive economic cost. The increase in regional directors (from 3 to 6) involved internal promotions, resulting in minimal additional cost. The new structure is expected to be easily offset by increased revenue due to enhanced focus.

    “As you know, 1099s, we pay a percent commission based on revenue. So the additive cost of those 1099s that I said in the discussion points were some of the best in the country. There's no economic additions to that. That's truly just a percent of revenue enhancement to our bottom line.”

    asked by Jeffrey Cohen · answered by Michael Fox

    2 min read5 chapters

    Detailed Narrative

    01

    Commercial Organization Transformation

    electroCore implemented significant changes to its commercial organization, including doubling the number of sales regions from three to six and realigning regional sales directors. The company recruited, contracted, and trained 17 new 1099 sales representatives, covering 29 VA medical centers, representing approximately 20% of the national VAMC network. These changes aim to enhance focus, leadership, and accountability within the sales team, improving customer value and patient advocacy.

    02

    VA and Federal Channel Expansion

    The company is focused on expanding its footprint within the VA and Department of Defense accounts. New 1099 reps have opened new VA accounts and expanded the number of new prescribers. Beyond the VA, electroCore made two targeted federal hires, including a 1099 representative for Kaiser outside California and a W-2 employee for Department of Defense and Federal Workers Compensation. The transition to Lovell Government Services as the sole federal supply schedule contract holder is expected to simplify procurement and cut G&A expenses by approximately 3%.

    03

    Product Portfolio and R&D Catalysts

    The VA remains a key growth driver, with gammaCore revenue up 11% year-over-year. The Quell product line, acquired in May 2025, saw sales of $1.3 million in Q2, growing 700% year-over-year. The company is pursuing an FDA submission for Chemotherapy-Induced Peripheral Neuropathy (CIPN) using the Quell device by year-end. Real-world studies with the Dorn Research Institute are underway to gather data on gammaCore's effects on PTSD, aiming for an expanded label in mild traumatic brain injury and PTSD. A next-generation clinical device incorporating biometrics and closed-loop vagal nerve stimulation is also in early development.

    04

    Operating Leverage and Profitability Path

    electroCore demonstrated continued operating leverage, with adjusted EBITDA improving 26% year-over-year and 25% sequentially. The company invested approximately $1 million in growth initiatives during the quarter. Management expects gross profit to increasingly fall to the bottom line as revenues expand, guiding for a sustainable gross profit margin of around 85%. The goal is to achieve positive adjusted EBITDA by Q3 2027 without additional dilutive capital raises, leveraging the expanded sales infrastructure against a largely fixed cost base.

    05

    Truvaga Performance and Market Dynamics

    Truvaga, the over-the-counter wellness brand, grew approximately 27% year-over-year to $1.3 million. However, media costs expanded due to increased competition, with the number of competitors bidding on Truvaga's branded search terms increasing by 60% (from 5 to 8) in the first half of 2026. This led to a 30% increase in direct cost per click and a reduction in the media efficiency ratio to 1.91. In response, the company reduced media spend by 2% while still achieving year-over-year growth.

    AI-generated summary of the company’s earnings call. Not investment advice.